Detalhe da pesquisa
1.
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Mol Cancer Ther
; 23(1): 84-91, 2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774393
2.
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
Mol Cancer Ther
; 22(9): 999-1012, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294948